ClinicalTrials.gg

Program

molnupiravir

Also written as “Molnupiravir”, “EIDD-2801” and “MK-4482”.

Its studies are mostly in COVID-19 · Renal Insufficiency · Coronavirus Infections, led by 4 companies.

Furthest: phase 3, since Sep 30, 202014 company-led studies, 1 open or runningNext primary completion: Jan 26, 2031 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck91 open or runningphase 3since Sep 30, 2020Sep 30, 2020Jan 26, 2031phase 3 · NCT06667700
Ridgeback Biotherapeutics, LP30 open or runningphase 2since May 26, 2020Apr 29, 2020none ahead
Geropharm10 open or runningno phasesince Dec 7, 2022Dec 7, 2022none ahead
Valenta Pharm JSC10 open or runningno phasesince Jun 6, 2022Jun 6, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2020First study: phase 1 study in Coronavirus InfectionsNew to Ridgeback Biotherapeutics, LPRidgeback Biotherapeutics, LP · NCT04392219 · 130 enrolled · United Kingdom
  2. May 26, 20202 phase 2 studiesRidgeback Biotherapeutics, LP · NCT04405739, NCT04405570
  3. Sep 30, 2020Merck's first studies: 2 phase 3 studies in COVID-19New to MerckMerck · NCT04575597, NCT04575584
  4. Jun 24, 2021Phase 3 study in COVID-19Merck · NCT04939428 · 2,441 enrolled · United States, Argentina, Brazil and more
  5. May 18, 20222 phase 1 studiesMerck · NCT05386758, NCT05386589
  6. Jun 6, 2022Valenta Pharm JSC's first study: no phase study in Virus DiseasesNew to Valenta Pharm JSCValenta Pharm JSC · NCT05412173 · 37 enrolled · Russian Federation
  7. Sep 26, 2022Phase 2 study in Respiratory Syncytial VirusMerck · NCT05559905 · 116 enrolled · United Kingdom
  8. Dec 7, 2022Geropharm's first study: no phase study in COVID-19New to GeropharmGeropharm · NCT05648799 · 246 enrolled · Russian Federation
  9. Sep 24, 2024Phase 1 study in HealthyMerck · NCT06615869 · 64 enrolled · United States
  10. Oct 30, 2024Phase 3 study in COVID-19Merck · NCT06667700 · 3,082 planned · United States, Argentina, Brazil and more
  11. Feb 4, 2025Phase 1 study in COVID-19Merck · NCT06816030 · 16 enrolled · China

Ahead

  1. Jan 26, 2031Primary completion: phase 3 study in COVID-19Merck · NCT06667700

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“RNA disrupting agent”ChEMBL 37, by rule

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06816030COVID-19 · China1CompletedMerckAug 5, 202316
NCT06667700COVID-19 · United States, Argentina, Brazil and more3RecruitingMerckJan 26, 20313,082
NCT06615869Healthy · United States1CompletedMerckFeb 27, 202364
NCT05648799COVID-19 · Russian Federation–CompletedGeropharmMay 11, 2022246
NCT05559905Respiratory Syncytial Virus · United Kingdom2CompletedMerckApr 18, 2023116
NCT05412173Virus Diseases · Russian Federation–CompletedValenta Pharm JSCMay 17, 202237
NCT05386758Renal Insufficiency · United States1CompletedMerckFeb 4, 202316
NCT05386589Hepatic Impairment · United States1CompletedMerckDec 18, 202214
NCT04939428COVID-19 · United States, Argentina, Brazil and more3CompletedMerckNov 16, 20222,441
NCT04575597COVID-19 · United States, Argentina, Brazil and more3CompletedMerckMay 5, 20221,735
NCT04575584COVID-19 · United States, Brazil, Canada and more3TerminatedMerckAug 11, 2021304
NCT04405739SARS-CoV 2 · United States2CompletedRidgeback Biotherapeutics, LPFeb 21, 202271
NCT04405570COVID-19 · United States2CompletedRidgeback Biotherapeutics, LPFeb 21, 2021204
NCT04392219Coronavirus Infections · United Kingdom1CompletedRidgeback Biotherapeutics, LPAug 11, 2020130

How it is read

Names in the registry

  • “Molnupiravir”, 9 entries
  • “EIDD-2801”, 2 entries
  • “MK-4482”, 1 entry
  • “GP30341 capsules 200 mg”, 1 entry
  • “Molnupiravir 200 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.